Predicting brain tumour enhancement from non-contrast MRI with artificial intelligence: a multicohort, retrospective, diagnostic accuracy study

Background

Brain tumour imaging assessment typically requires both pre-contrast and post-contrast MRI, but gadolinium administration is not always desirable-for example, in patients requiring frequent follow-up, or those with renal impairment or allergy, or those who are of pediatric age [0-18 years]. We aimed to develop and validate a deep learning model to predict brain tumour contrast enhancement from non-contrast MRI sequences alone.